Sitemap - 2024 - Divergent Capital Investment Research

Initial Thoughts on Recent Events at Moberg.

Notes from Cipher Pharmaceuticals' Planet Microcap Interview dated 21 August 2024.

Estimate of Cipher Pharmaceuticals' Potential Future Operating Income Post-Natroba Acquisition.

OTC-Listed, U.S. Nanocap with High-Insider Ownership, No Institutional Ownership, 26% of Market Cap in Cash & Investments, High ROIC, Trading at a Discount.

Initial Thoughts on Cipher's Acquisition of ParaPRO's, "Natroba"

Haypp Group AB: A Fly-Wheel Business Surfing the Nicotine Pouch Tidal Wave, Positioned to Thrive Amidst Intense Competition

Haypp Group AB: Write-Up Preview

BQE Water: A Capital-Light Compounder with Expanding Margins and Long-Term Recurring Revenues

BQE Water: Write-Up Preview

Moberg Pharma AB: A Royalty on an Innovative Treatment for a Condition Affecting Hundreds of Millions of People Globally

Cipher Pharmaceuticals: A High ROIC Legacy Business at a Fair Price with a Free Call-Option on Two Unpriced Catalysts

My Value Investing Conceptual Framework in the Tradition of Graham, Buffett and Munger.

Cipher Pharmaceuticals: Write-Up Preview

Moberg Pharma AB: Write-Up Preview

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts